These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38073182)

  • 1. Hip Displacement in Spinal Muscular Atrophy: The Influences of Genetic Severity, Functional Level, and Disease-modifying Treatments.
    Ulusaloglu AC; Asma A; Shrader MW; Scavina MT; Mackenzie WG; Erb A; Howard JJ
    J Pediatr Orthop; 2024 Mar; 44(3):e226-e231. PubMed ID: 38073182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scoliosis Development in Spinal Muscular Atrophy: The Influences of Genetic Severity, Functional Level, and Disease-Modifying Treatments.
    Ciftci S; Ulusaloglu AC; Shrader MW; Scavina MT; Mackenzie WG; Heinle R; Neal KM; Stall A; Howard JJ
    J Pediatr Orthop; 2024 Jun; ():. PubMed ID: 38916214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug treatment for spinal muscular atrophy types II and III.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD006282. PubMed ID: 32006461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis.
    Toro W; Yang M; Georgieva M; Song W; Patel A; Jiang AX; Zhao A; LaMarca N; Dabbous O
    Adv Ther; 2023 Oct; 40(10):4589-4605. PubMed ID: 37587305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nusinersen Initiation After Onset of Weakness Does Not Prevent Progression of Hip Instability.
    Kuong EE; Ip HNH; So NLW; To MKT; Chow W; Wong JSH; Chan SHS
    J Pediatr Orthop; 2024 Aug; 44(7):e657-e661. PubMed ID: 38689487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spinal muscular atrophy: survival pattern and functional status.
    Chung BH; Wong VC; Ip P
    Pediatrics; 2004 Nov; 114(5):e548-53. PubMed ID: 15492357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Responsiveness of the motor function measure in patients with spinal muscular atrophy.
    Vuillerot C; Payan C; Iwaz J; Ecochard R; Bérard C;
    Arch Phys Med Rehabil; 2013 Aug; 94(8):1555-61. PubMed ID: 23380348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison.
    Ribero VA; Daigl M; Martí Y; Gorni K; Evans R; Scott DA; Mahajan A; Abrams KR; Hawkins N
    J Comp Eff Res; 2022 Apr; 11(5):347-370. PubMed ID: 35040693
    [No Abstract]   [Full Text] [Related]  

  • 9. Later efficacy of nusinersen treatment in adult patients with spinal muscular atrophy: A retrospective case study with a median 4-year follow-up.
    Funato M; Kino A; Iwata R; Yumioka M; Yamashita K; Urui C; Uno R; Kondo E; Morioka E; Ogawa Y; Kawamura A; Kusukawa T; Minatsu H
    Brain Dev; 2024 Jan; 46(1):62-67. PubMed ID: 37657961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study.
    Yang H; Tao Q; Li D; Yang J; Cai Q; Gan J; Huang S; Luo R
    BMC Neurol; 2023 Jan; 23(1):35. PubMed ID: 36690929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nusinersen for spinal muscular atrophy types II and III: a retrospective single-center study in South Korea.
    Shin HJ; Na JH; Lee H; Lee YM
    World J Pediatr; 2023 May; 19(5):450-459. PubMed ID: 36441395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug treatment for spinal muscular atrophy type I.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD006281. PubMed ID: 31825542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study.
    Stettner GM; Hasselmann O; Tscherter A; Galiart E; Jacquier D; Klein A
    BMC Neurol; 2023 Feb; 23(1):88. PubMed ID: 36855136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG).
    Finkel RS; Darras BT; Mendell JR; Day JW; Kuntz NL; Connolly AM; Zaidman CM; Crawford TO; Butterfield RJ; Shieh PB; Tennekoon G; Brandsema JF; Iannaccone ST; Shoffner J; Kavanagh S; Macek TA; Tauscher-Wisniewski S
    J Neuromuscul Dis; 2023; 10(3):389-404. PubMed ID: 36911944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study.
    Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Wenzel F; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Walter MC; Bertsche A; Vill K; Baumann M; Baumgartner M; Cordts I; Eisenkölbl A; Flotats-Bastardas M; Friese J; Günther R; Hahn A; Horber V; Husain RA; Illsinger S; Jahnel J; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schwerin-Nagel A; Reihle C; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Trollmann R; Weiler M; Weiß C; Wiegand G; Wilichowski E; Ziegler A; Lochmüller H; Kirschner J;
    Orphanet J Rare Dis; 2022 Oct; 17(1):384. PubMed ID: 36274155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muscle impairment in MRI affect variability in treatment response to nusinersen in patients with spinal muscular atrophy type 2 and 3: A retrospective cohort study.
    Shimizu-Motohashi Y; Chiba E; Mizuno K; Yajima H; Ishiyama A; Takeshita E; Sato N; Oba M; Sasaki M; Ito S; Komaki H
    Brain Dev; 2023 Mar; 45(3):161-170. PubMed ID: 36460551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Data from Nusinersen Treatment for Patients with Later-Onset Spinal Muscular Atrophy: A Single Center Experience.
    Mendonça RH; Polido GJ; Matsui C; Silva AMS; Solla DJF; Reed UC; Zanoteli E
    J Neuromuscul Dis; 2021; 8(1):101-108. PubMed ID: 33074187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determining minimal clinically important differences in the Hammersmith Functional Motor Scale Expanded for untreated spinal muscular atrophy patients: An international study.
    Coratti G; Bovis F; Pera MC; Scoto M; Montes J; Pasternak A; Mayhew A; Muni-Lofra R; Duong T; Rohwer A; Dunaway Young S; Civitello M; Salmin F; Mizzoni I; Morando S; Pane M; Albamonte E; D'Amico A; Brolatti N; Sframeli M; Marini-Bettolo C; Sansone VA; Bruno C; Messina S; Bertini E; Baranello G; Day J; Darras BT; De Vivo DC; Hirano M; Muntoni F; Finkel R; Mercuri E;
    Eur J Neurol; 2024 Aug; 31(8):e16309. PubMed ID: 38656662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry.
    Servais L; Day JW; De Vivo DC; Kirschner J; Mercuri E; Muntoni F; Proud CM; Shieh PB; Tizzano EF; Quijano-Roy S; Desguerre I; Saito K; Faulkner E; Benguerba KM; Raju D; LaMarca N; Sun R; Anderson FA; Finkel RS
    J Neuromuscul Dis; 2024; 11(2):425-442. PubMed ID: 38250783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hip Displacement in MECP2 Disorders: Prevalence and Risk Factors.
    Kanashvili B; Rogers KJ; Shrader MW; Miller F; Dabney KW; Howard JJ
    J Pediatr Orthop; 2021 Oct; 41(9):e800-e803. PubMed ID: 34334698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.